Optimized regimens of combined medications for the treatment of major depressive disorder: a double-blind, randomized-controlled trial
Zoë Zuilhof, Sandhaya Norris, Claude Blondeau, Pierre Tessier, Pierre Blier Department of Psychiatry, University of Ottawa, The Royal Ottawa Institute of Mental Health Research, Ottawa, ON, Canada Introduction: This study investigated if optimized dose regimens of escitalopram and bupropi...
Enregistré dans:
Auteurs principaux: | Zuilhof Z, Norris S, Blondeau C, Tessier P, Blier P |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/9d33968dcc3f457d80e20b1b7ceec6e4 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Escitalopram, bupropion, lurasidone, lamotrigine and possible vortioxetine overdose presented with serotonin syndrome and diffuse encephalopathy: A case report
par: Suthimon Thumtecho, et autres
Publié: (2021) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
par: Kishi T, et autres
Publié: (2017) -
Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
par: Maneeton B, et autres
Publié: (2018) -
Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment
par: Xue-Qin Wang, et autres
Publié: (2021) -
Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study
par: Baune BT, et autres
Publié: (2021)